Invasive Management of Coronary Artery Disease in Advanced Renal Disease.

Abstract

Coronary artery disease (CAD) is highly prevalent in chronic kidney disease (CKD). CKD modifies the effects of traditional risk factors on atherosclerosis, with CKD-specific mechanisms, such as inflammation and altered mineral metabolism, playing a dominant pathophysiological role as kidney function declines. Traditional risk models and cardiovascular screening tests perform relatively poorly in the CKD population, and medical treatments including lipid-lowering therapies have reduced efficacy. Clinical presentation of cardiac ischemia in CKD is atypical, whereas invasive therapies are associated with higher rates of complications than in with patients with normal or near normal kidney function. The main focus of the present review is on the invasive approach to management of CAD in late-stage CKD, with an in-depth discussion of the findings of the International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)-CKD trial, and their implications for therapeutic approach and future research in this area. We also briefly discuss the existing evidence in the epidemiology, pathogenesis, diagnosis, and medical management of CAD in late-stage CKD, end-stage kidney disease (ESKD), and kidney transplant recipients. We enumerate the evidence gap left by the frequent exclusion of patients with CKD from randomized controlled trials and highlight the priority areas for future research in the CKD population.

• Authors: Keyvan Karimi Galougahi, Steven Chadban, Roxana Mehran, Sripal Bangalore, Glenn M Chertow, Ziad A Ali
• Journal: Kidney international reports (Kidney Int Rep) Vol. 6 Issue 6 Pg. 1513-1524 (Jun 2021) ISSN: 2468-0249 [Electronic] United States
• PMID: 34169192 (Publication Type: Journal Article, Review)
• Copyright: © 2021 International Society of Nephrology. Published by Elsevier Inc.